NEUROCRINE BIOSCIENCES INC
For the period ended Nov 2, 2026. Filed Nov 2, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Nov 2, 2026 · Filed Nov 2, 2026
Use the contents to explore the available documents and sections.
NBIX$164.63+3.0%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · TABLE
TABLE 3
| Three Months EndedSeptember 30, | Nine Months EndedSeptember 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| GAAP net income 1 | $206.5 | $209.5 | $548.8 | $324.9 |
| Adjustments: | ||||
| Stock-based compensation expense | 54.3 | 53.7 | 176.5 | 159.3 |
| Acceleration of stock-based compensation expense and related taxes 2 | — | — | 60.1 | — |
| Acquisition-related employee compensation and severance costs | 16.7 | — | 38.6 | — |
| Amortization of inventory fair value step-up 3 | 6.3 | — | 9.3 | — |
| Amortization of acquired intangible assets 4 | 35.0 | 1.0 | 51.5 | 3.0 |
| Acquisition/divestiture-related transaction and integration costs | 1.9 | — | 50.6 | — |
| Gain on sale of business, net of transaction costs 5 | — | — | (28.6) | — |
| Changes in fair values of equity investments 6 | 52.3 | (30.6) | 25.8 | 6.7 |
| Other 7 | 1.9 | 0.8 | 3.2 | 3.1 |
| Income tax effect related to reconciling items 8 | (28.2) | (12.3) | (91.9) | (37.1) |
| Non-GAAP net income 1 | $346.7 | $222.1 | $843.9 | $459.9 |
| Diluted earnings per share: | ||||
| GAAP | $1.96 | $2.04 | $5.26 | $3.19 |
| Non-GAAP | $3.29 | $2.17 | $8.09 | $4.51 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.